Company: EVLVW
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001628280-25-021091
Chunk: 60

Company: Evolv Technologies Holdings, Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 60
---
 Granted in the Fiscal Year                                                     |     |                  |    855,001 |     |                  |  3,236,686 |
| Plus/(Minus):Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Fiscal Years                                                   |     |                  |   -202,962 |     |                  |    782,756 |
| Plus:Fair Value at Vesting of Equity Awards Granted and Vested in the Fiscal Year                                                                           |     |                  |    123,888 |     |                  |    176,261 |
| Plus/(Minus):Change in Fair Value as of the Vesting Date of Equity Awards Granted in Prior Fiscal Years that Vested in the Fiscal Year                      |     |                  |   -574,064 |     |                  |    653,144 |
| (Minus):Fair Value as of the Prior Fiscal Year End of Equity Awards Granted in Prior Fiscal Years that Failed to Meet Vesting Conditions in the Fiscal Year |     |                  | -1,250,587 |     |                  |          — |
| Plus:Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation                                               |     |                  |          — |     |                  |          — |
| Compensation Actually Paid                                                                                                                                  |     | $                |   -612,591 |     | $                |  5,216,512 |

(A) Messrs. Kedzierski and Ellenbogen were not named executive officers for the fiscal year ended December 31, 2023, and therefore SCT information has only been provided for the fiscal year ended December 31, 2024.

For purposes of the above adjustments, the fair value of equity awards on the applicable date were determined in accordance with FASB’s ASC Topic 718, using valuation methodologies that are generally consistent with those used to determine the grant-date fair value for accounting purposes.

<div align='center'>48</div>

TABLE OF CONTENTS

The assumptions used in calculating the fair value of the equity awards did not differ in any material respect from the assumptions used to calculate the grant date fair value of the awards as reported in the Summary Compensation Table, except that the fair value calculations of (i) the options granted on 3/4/2024 used an expected term between 4.8 years and 7.4 years, as compared to an expected term of 6.1 years used to calculate the grant date fair value of such awards.

(4)